NETRIS Pharma
- Biotech or pharma, therapeutic R&D
Netris Pharma is a clinical-stage company developing innovative therapeutics to improve treatment outcome for cancer patients. Our lead asset, NP137, is a first-in-class anti-Netrin1 monoclonal antibody currently investigated in 5 clinical trials with multiple efficacy readouts expected in H2 2025
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}